Literature DB >> 22444545

Increasing opsonizing and killing effect of serum from patients with recurrent K1 Klebsiella pneumoniae liver abscess.

Fang-Ching Yeh1, Kao-Ming Yeh, L K Siu, Chang-Phone Fung, Ya-Sung Yang, Jung-Chung Lin, Feng-Yee Chang.   

Abstract

BACKGROUND: Klebsiella pneumoniae liver abscess (KLA) is an emerging infectious disease caused by the virulent K pneumoniae strains of capsular serotype K1 and commonly associated with diabetes mellitus. Recurrent KLA is rarely reported and the mechanism of recurrence is uncertain. In this study we evaluated both phagocytosis by neutrophils and serum killing ability of serum from recurrent K1 KLA patients compared to normal healthy subjects (NHS).
METHODS: This prospective study included six cases of recurrent K1 KLA consisting of three male and three female patients with a mean age of 67.2 years (range, 56-88 years). The different serotypes of K pneumoniae were reacted with serum from patients with recurrent KLA and NHS. Subsequent phagocytosis by neutrophils was determined using flow cytometry and serum killing assays were performed.
RESULTS: The most common underlying disease in patients with recurrent KLA was diabetes mellitus, occurring in about 83.3% (5/6) of patients. The antibiogram of the strains associated with recurrent KLA remained uniquely resistant to ampicillin. The average percentage derived from the serum killing assays showed serotype K1 and K2 resistance to serum from NHS (1281% and 621%, respectively); however, serum susceptibly was observed in the serum of patients with recurrent K1 KLA (0.3% and 1.1%, respectively). A significant increase in neutrophil phagocytosis of serotype K1 was observed following opsonisation with serum from patients with recurrent KLA compared with serum from NHS (p = 0.008). No significant difference in the phagocytic rate of non-K1/K2 or K2 serotypes was observed between NHS and patients with recurrent KLA (p = 0.76 and p = 0.132, respectively).
CONCLUSION: These preliminary results showed possible immunologic protection in patients with recurrent KLA due to increasing opsonization and serum killing.
Copyright © 2011. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22444545     DOI: 10.1016/j.jmii.2011.12.006

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN: 1684-1182            Impact factor:   4.399


  5 in total

1.  Antibody-Based Immunotherapy To Treat and Prevent Infection with Hypervirulent Klebsiella pneumoniae.

Authors:  Elizabeth Diago-Navarro; Isabel Calatayud-Baselga; Donglei Sun; Camille Khairallah; Inderjit Mann; Amaia Ulacia-Hernando; Brian Sheridan; Meiqing Shi; Bettina C Fries
Journal:  Clin Vaccine Immunol       Date:  2017-01-05

2.  Fitness Cost of Daptomycin-Resistant Staphylococcus aureus Obtained from in Vitro Daptomycin Selection Pressure.

Authors:  Shuguang Li; Yuyao Yin; Hongbin Chen; Qi Wang; Xiaojuan Wang; Hui Wang
Journal:  Front Microbiol       Date:  2017-11-09       Impact factor: 5.640

3.  Genetic characterization and passage instability of a novel hybrid virulence plasmid in a ST23 hypervirulent Klebsiella pneumoniae.

Authors:  Lin-Ping Fan; Yang Yu; Shanshan Huang; Wenjian Liao; Qi-Sen Huang; Fang-Ling Du; Tian-Xin Xiang; Dan Dan Wei; La-Gen Wan; Wei Zhang; Yang Liu
Journal:  Front Cell Infect Microbiol       Date:  2022-07-28       Impact factor: 6.073

Review 4.  An Increasing Prominent Disease of Klebsiella pneumoniae Liver Abscess: Etiology, Diagnosis, and Treatment.

Authors:  Yun Liu; Ji-Yao Wang; Wei Jiang
Journal:  Gastroenterol Res Pract       Date:  2013-09-30       Impact factor: 2.260

5.  Interaction of non-human primate complement and antibodies with hypermucoviscous Klebsiella pneumoniae.

Authors:  Esteban Soto; Sylvia Marchi; Amy Beierschmitt; Michael Kearney; Stewart Francis; Kimberly VanNess; Michel Vandenplas; MaryAnna Thrall; Roberta Palmour
Journal:  Vet Res       Date:  2016-03-08       Impact factor: 3.683

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.